pf-06463922 and Hyperlipidemias

pf-06463922 has been researched along with Hyperlipidemias* in 2 studies

Reviews

1 review(s) available for pf-06463922 and Hyperlipidemias

ArticleYear
A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:8

    We report the case of a woman who developed hyperlipidemia on lorlatinib therapy found to have minimal change disease. We review therapies for cancer known to alter the lipid profile, in addition to reviewing secondary hyperlipidemia workup. We also propose a mechanism for lorlatinib-induced hyperlipidemia.. A 63 year old woman with non-small cell lung adenocarcinoma on lorlatinib therapy develops marked hyperlipidemia.. This is a case of hyperlipidemia in a patient on lorlatinib. The case highlights that therapies for lung cancer and other malignancies have the potential to alter the lipid profile. We propose minimal change disease as a possible mechanism for lorlatinib-induced dyslipidemia. Additionally, we discuss the crucial aspects of secondary hyperlipidemia workup.

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hyperlipidemias; Lactams; Lung Neoplasms; Middle Aged; Pyrazoles

2021

Trials

1 trial(s) available for pf-06463922 and Hyperlipidemias

ArticleYear
First-Line Lorlatinib or Crizotinib in Advanced
    The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21

    Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with. We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced. The percentage of patients who were alive without disease progression at 12 months was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; P<0.001). An objective response occurred in 76% (95% CI, 68 to 83) of the patients in the lorlatinib group and 58% (95% CI, 49 to 66) of those in the crizotinib group; among those with measurable brain metastases, 82% (95% CI, 57 to 96) and 23% (95% CI, 5 to 54), respectively, had an intracranial response, and 71% of the patients who received lorlatinib had an intracranial complete response. The most common adverse events with lorlatinib were hyperlipidemia, edema, increased weight, peripheral neuropathy, and cognitive effects. Lorlatinib was associated with more grade 3 or 4 adverse events (mainly altered lipid levels) than crizotinib (in 72% vs. 56%). Discontinuation of treatment because of adverse events occurred in 7% and 9% of the patients, respectively.. In an interim analysis of results among patients with previously untreated advanced

    Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Hyperlipidemias; Intention to Treat Analysis; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation; Pyrazoles; Survival Analysis

2020